Natural Product (NP) Details
General Information of the NP (ID: NP8057) | |||||
---|---|---|---|---|---|
Name |
Parthenolide
|
||||
Synonyms |
parthenolide; 20554-84-1; (-)-Parthenolide; MFCD00134592; CHEBI:7939; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; (1aR,4E,7aS,10aS,10bR)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one; (3aS,9aR,10aR,10bS,E)-6,9a-dimethyl-3-methylene-3a,4,5,8,9,9a,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-2(3H)-one; 29552-41-8; partenolide; Parthenolide, Tanacetum parthenium; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_000599; BSPBio_001308; MLS002153872; BPBio1_000659; CHEMBL465158; parthenolide-(alternate-stereo); SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, >=98% (HPLC); HMS1361B10; HMS1569N21; HMS1791B10; HMS1989B10; HMS2096N21; HMS3402B10; HMS3713N21; BCP10404; HY-N0141; ZINC4492886; AKOS016010226; CCG-208244; CS-1919; IDI1_033778; NCGC00163415-01; NCGC00163415-04; AS-17479; SMR001233226; AB0019832; AB00513860; V0355; X-1866; 552P418; Q-100253; (-)-Parthenolide; NSC-157035; NSC 157035; NSC157035; Parthenolide, United States Pharmacopeia (USP) Reference Standard; (1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one; (3aS,10R,11R,11aS,6E)-3-Methylene-6,10-dimethyl-10,11-epoxy-1-oxa-2,3,3a,4,5,8,9,10,11,11a-decahydro-1H-cyclopentacyclodecene-2-one
Click to Show/Hide
|
||||
Species Origin | Tanacetum parthenium ... | Click to Show/Hide | |||
Tanacetum parthenium | |||||
Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H20O3
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C
|
||||
InChI |
1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
|
||||
InChIKey |
KTEXNACQROZXEV-PVLRGYAZSA-N
|
||||
CAS Number |
CAS 20554-84-1
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Balsalazide | Indeterminate colitis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
In-vivo Model | Sixty specific pathogen-free mice (Balb/C female mice, 6 week) were used in this study. | |||||
Experimental
Result(s) |
Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Epirubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Parthenolide along with Epirubicin chemotherapy drug could improve cytotoxicity and apoptosis and reduces IC50. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | I-kappa-B-kinase beta (IKKB) | Molecule Info | [4] | |
Nuclear factor NF-kappa-B (NFKB) | Molecule Info | [5] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | Ras signaling pathway | |||
3 | Chemokine signaling pathway | |||
4 | NF-kappa B signaling pathway | |||
5 | FoxO signaling pathway | |||
6 | mTOR signaling pathway | |||
7 | PI3K-Akt signaling pathway | |||
8 | Apoptosis | |||
9 | Osteoclast differentiation | |||
10 | Toll-like receptor signaling pathway | |||
11 | NOD-like receptor signaling pathway | |||
12 | RIG-I-like receptor signaling pathway | |||
13 | Cytosolic DNA-sensing pathway | |||
14 | T cell receptor signaling pathway | |||
15 | B cell receptor signaling pathway | |||
16 | TNF signaling pathway | |||
17 | Neurotrophin signaling pathway | |||
18 | Insulin signaling pathway | |||
19 | Adipocytokine signaling pathway | |||
20 | Type II diabetes mellitus | |||
21 | Non-alcoholic fatty liver disease (NAFLD) | |||
22 | Epithelial cell signaling in Helicobacter pylori infection | |||
23 | Shigellosis | |||
24 | Chagas disease (American trypanosomiasis) | |||
25 | Toxoplasmosis | |||
26 | Hepatitis C | |||
27 | Hepatitis B | |||
28 | Influenza A | |||
29 | HTLV-I infection | |||
30 | Herpes simplex infection | |||
31 | Epstein-Barr virus infection | |||
32 | Pathways in cancer | |||
33 | MicroRNAs in cancer | |||
34 | Pancreatic cancer | |||
35 | Prostate cancer | |||
36 | Chronic myeloid leukemia | |||
37 | Acute myeloid leukemia | |||
38 | Small cell lung cancer | |||
39 | Legionellosis | |||
40 | Viral carcinogenesis | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | B cell activation | |||
3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
4 | Interleukin signaling pathway | |||
5 | PDGF signaling pathway | |||
6 | T cell activation | |||
7 | Toll receptor signaling pathway | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | BCR signaling pathway | |||
3 | GMCSF-mediated signaling events | |||
4 | Atypical NF-kappaB pathway | |||
5 | TCR signaling in naï | |||
6 | ||||
7 | Canonical NF-kappaB pathway | |||
8 | TRAIL signaling pathway | |||
9 | TCR signaling in naï | |||
10 | ||||
11 | FAS (CD95) signaling pathway | |||
12 | IL1-mediated signaling events | |||
13 | mTOR signaling pathway | |||
14 | TNF receptor signaling pathway | |||
15 | FoxO family signaling | |||
16 | p75(NTR)-mediated signaling | |||
17 | Validated transcriptional targets of TAp63 isoforms | |||
18 | Endogenous TLR signaling | |||
19 | IL12-mediated signaling events | |||
20 | Alternative NF-kappaB pathway | |||
Reactome | Activation of NF-kappaB in B cells | Click to Show/Hide | ||
2 | NOD1/2 Signaling Pathway | |||
3 | RIP-mediated NFkB activation via ZBP1 | |||
4 | p75NTR recruits signalling complexes | |||
5 | NF-kB is activated and signals survival | |||
6 | FCERI mediated NF-kB activation | |||
7 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
8 | Interleukin-1 signaling | |||
9 | Regulation of TNFR1 signaling | |||
10 | TNFR1-induced NFkappaB signaling pathway | |||
11 | IKBKB deficiency causes SCID | |||
12 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
13 | IkBA variant leads to EDA-ID | |||
14 | CLEC7A (Dectin-1) signaling | |||
15 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
16 | TRAF6 mediated NF-kB activation | |||
17 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | |||
18 | IRAK1 recruits IKK complex | |||
19 | IKK complex recruitment mediated by RIP1 | |||
20 | IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | |||
21 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
22 | Interleukin-1 processing | |||
23 | Dectin-1 mediated noncanonical NF-kB signaling | |||
24 | NIK-->noncanonical NF-kB signaling | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Estrogen signaling pathway | |||
3 | TCR Signaling Pathway | |||
4 | Insulin Signaling | |||
5 | IL-4 Signaling Pathway | |||
6 | MAPK Signaling Pathway | |||
7 | NLR Proteins | |||
8 | Hair Follicle Development: Induction (Part 1 of 3) | |||
9 | MyD88 cascade initiated on plasma membrane | |||
10 | Cardiac Hypertrophic Response | |||
11 | Cytosolic sensors of pathogen-associated DNA | |||
12 | MyD88 dependent cascade initiated on endosome | |||
13 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
14 | MyD88:Mal cascade initiated on plasma membrane | |||
15 | Fc epsilon receptor (FCERI) signaling | |||
16 | MyD88-independent cascade | |||
17 | Signaling by the B Cell Receptor (BCR) | |||
18 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
19 | Structural Pathway of Interleukin 1 (IL-1) | |||
20 | EBV LMP1 signaling | |||
21 | Polycystic Kidney Disease Pathway | |||
22 | Apoptosis | |||
23 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
24 | BDNF signaling pathway | |||
25 | Interleukin-11 Signaling Pathway | |||
26 | AGE/RAGE pathway | |||
27 | TNF alpha Signaling Pathway | |||
28 | B Cell Receptor Signaling Pathway | |||
29 | IL17 signaling pathway | |||
30 | TWEAK Signaling Pathway | |||
31 | Leptin signaling pathway | |||
32 | RANKL/RANK Signaling Pathway | |||
33 | Signalling by NGF | |||
34 | IL-1 signaling pathway | |||
35 | TCR signaling | |||
36 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
37 | Interleukin-1 signaling | |||
38 | Apoptosis Modulation and Signaling | |||
39 | Type II diabetes mellitus | |||
40 | MicroRNAs in cardiomyocyte hypertrophy | |||
41 | Regulation of toll-like receptor signaling pathway | |||
42 | Osteopontin Signaling | |||
43 | NOD pathway | |||
44 | DNA Damage Response (only ATM dependent) | |||
45 | SIDS Susceptibility Pathways | |||
46 | Nuclear Receptors Meta-Pathway | |||
47 | TSLP Signaling Pathway | |||
48 | Neural Crest Differentiation | |||
49 | Interleukin-1 processing | |||
50 | Folate Metabolism | |||
51 | Vitamin B12 Metabolism | |||
52 | Selenium Micronutrient Network |